|
传染性B型流感病毒/香港/574/2019[B-维多利亚系]21/124
|
EA
|
21/124
|
咨询
|
1-4/12周
|
|
流感病毒传染性SAN-004A[H3N2]21/130
|
EA
|
21/130
|
咨询
|
1-4/12周
|
|
流感抗原A/塔斯马尼亚/503/2020[IVR-221][H3N2]21/116
|
EA
|
21/116
|
4081
|
1-4/12周
|
|
流感抗A/Victoria/2570/2019样[H1N1]HA血清21/120
|
EA
|
21/120
|
4081
|
1-4/12周
|
|
流感病毒传染性X-357A[H3N2]21/122
|
EA
|
21/122
|
咨询
|
1-4/12周
|
|
流感抗原A/柬埔寨/e0826360/2020[IVR-224][H3N2]21/100
|
EA
|
21/100
|
4081
|
1-4/12周
|
|
甲型流感病毒/新加坡/INFIMH-16-0019/2016[H3N2]20/322
|
EA
|
20/322
|
咨询
|
1-4/12周
|
|
拉沙病毒RNA21/110工作试剂
|
EA
|
21/110
|
4502
|
1-4/12周
|
|
第2批WHO国际脑膜炎球菌荚膜C组多糖标准20/314
|
EA
|
20/314
|
4988
|
1-4/12周
|
|
流感病毒传染性IVR-221[H3N2]20/318
|
EA
|
20/318
|
咨询
|
1-4/12周
|
|
第1批WHO拉沙病毒RNA国际标准21/112
|
EA
|
21/112
|
4988
|
1-4/12周
|
|
XIII因子血浆的第2批国际标准,人源20/292
|
EA
|
20/292
|
4988
|
1-4/12周
|
|
流感病毒传染性X-347A[H3N2]20/296
|
EA
|
20/296
|
咨询
|
1-4/12周
|
|
WHO用于NGSGUT微生物组分析的国际参考试剂[Gut-MixRR]20/302
|
EA
|
20/302
|
4988
|
1-4/12周
|
|
流感病毒传染性X-347[H3N2]20/294
|
EA
|
20/294
|
咨询
|
1-4/12周
|
|
传染性A型流感病毒/柬埔寨/E0826360/2020[H3N2]20/310
|
EA
|
20/310
|
咨询
|
1-4/12周
|
|
用于通过NGS进行GUT微生物组分析的WHO参考试剂[DNA-Gut-HiLo]20/304
|
EA
|
20/304
|
4988
|
1-4/12周
|
|
WHO参考试剂脊髓灰质炎病毒1、2和3型人单克隆抗体20/256
|
EA
|
20/256
|
4988
|
1-4/12周
|
|
世界卫生组织2型脊髓灰质炎病毒人单克隆抗体参考试剂20/252
|
EA
|
20/252
|
4988
|
1-4/12周
|
|
世界卫生组织3型脊髓灰质炎病毒人单克隆抗体参考试剂20/254
|
EA
|
20/254
|
4988
|
1-4/12周
|